These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
121 related articles for article (PubMed ID: 10298125)
1. The tripartite reimbursement incentive model: a new method to eliminate the discounting of the copayment charge. Paul SH Med Mark Media; 1981 Mar; 16(3):35-9. PubMed ID: 10298125 [No Abstract] [Full Text] [Related]
2. Competitive incentive program. Analysis and proposal. Stone J Am Pharm; 1986 Jul; NS26(7):45-9. PubMed ID: 3529904 [No Abstract] [Full Text] [Related]
3. Copayment for pharmaceutical services in a Medicaid program. Nelson AA; Quick MR Contemp Pharm Pract; 1980; 3(1):37-42. PubMed ID: 10297666 [TBL] [Abstract][Full Text] [Related]
5. Tier 4 drugs and the fraying of the social compact. Lee TH; Emanuel EJ N Engl J Med; 2008 Jul; 359(4):333-5. PubMed ID: 18650510 [No Abstract] [Full Text] [Related]
6. Potential impact of prepayment on Medicaid drug costs. Yesalls CE; Norwood GJ; Lipson DP Contemp Pharm Pract; 1979; 2(2):87-94. PubMed ID: 10297462 [No Abstract] [Full Text] [Related]
7. Lost in the doughnut hole. The drug benefit's woes will worsen as seniors discover shortcomings. Sloane T Mod Healthc; 2006 Jan; 36(3):24. PubMed ID: 16445210 [No Abstract] [Full Text] [Related]
8. Medicaid and indigent care issue brief: Medicaid: provider reimbursement: year end report-2003. Johnson P Issue Brief Health Policy Track Serv; 2003 Dec; ():1-25. PubMed ID: 14969256 [TBL] [Abstract][Full Text] [Related]
9. State insurance commissioners weigh PBM regulations this month. Carlson B Manag Care; 2000 Mar; 9(3):19-20. PubMed ID: 11066209 [No Abstract] [Full Text] [Related]
10. Copayments for medications in 2012. Final rule. Department of Veterans Affairs Fed Regist; 2012 May; 77(93):28258-9. PubMed ID: 22606731 [TBL] [Abstract][Full Text] [Related]
11. Medicare part D--what doctors need to know. Stephenson L Iowa Med; 2005; 95(6):24-5. PubMed ID: 16425707 [No Abstract] [Full Text] [Related]
12. Third-party reimbursement: new concepts and contemporary issues. Paul SH; McEvilla JD Med Mark Media; 1980 Oct; 15(10):58-61, 64-70. PubMed ID: 10249123 [No Abstract] [Full Text] [Related]
13. Pharmaceuticals and medical devices: Medicare Part D. End-of-year issue brief. Chaps NA Issue Brief Health Policy Track Serv; 2008 Jan; ():1-23. PubMed ID: 18345558 [No Abstract] [Full Text] [Related]
14. Consumer response to dual incentives under multitiered prescription drug formularies. Gilman BH; Kautter J Am J Manag Care; 2007 Jun; 13(6 Pt 2):353-9. PubMed ID: 17567236 [TBL] [Abstract][Full Text] [Related]
15. Pharmaceuticals and medical devices: Medicare Part D. End-of-year issue brief. Chaps NA Issue Brief Health Policy Track Serv; 2009 Jan; ():1-26. PubMed ID: 19301435 [No Abstract] [Full Text] [Related]
17. Health plans, CMS agree to reimburse States' stopgap drug coverage for dual eligibles. Med Health; 2006 Jan; 60(6):1, 4. PubMed ID: 16475445 [No Abstract] [Full Text] [Related]
18. The Medicare prescription drug benefit poses opportunities for disease management. Kozma CM Manag Care Interface; 2004 Feb; 17(2):47-8. PubMed ID: 15038693 [No Abstract] [Full Text] [Related]
19. The effect of a Medicaid drug copayment program on the utilization and cost of prescription services. Nelson AA; Reeder CE; Dickson WM Med Care; 1984 Aug; 22(8):724-36. PubMed ID: 6433121 [TBL] [Abstract][Full Text] [Related]
20. Capitation reimbursement for pharmacy services: a dissenting view. Gosselin RA Med Mark Media; 1980 Oct; 15(10):51-6. PubMed ID: 10249122 [No Abstract] [Full Text] [Related] [Next] [New Search]